BSE: 532998 | NSE: LOTUSEYE | Hospital & Healthcare Services | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Lotus Eye Hospital And Institute Ltd is a below average quality company.
The key valuation ratios of Lotus Eye Hospital And Institute Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Lotus Eye Hospital And Institute Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -4.1% | 0.3% | 1.1% | 3.7% | 1.7% | 3.3% | 4.1% | 8% | 10.4% | 7.2% | - |
| Value Creation Index ⓘ | -1.3 | -1.0 | -0.9 | -0.7 | -0.9 | -0.8 | -0.7 | -0.4 | -0.3 | -0.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 29.9 | 31.1 | 34 | 38 | 38.4 | 40.6 | 32.4 | 38.9 | 47 | 48.2 | 49 |
| Sales YoY Gr. | - | 4.1% | 9.1% | 12% | 1.1% | 5.5% | -20.2% | 20.2% | 20.9% | 2.5% | - |
| Adj EPS ⓘ | -1 | 0.1 | 0.2 | 0.8 | 0.3 | 0.8 | 0.7 | 1.4 | 2 | 1.4 | 0.7 |
| YoY Gr. | - | NA | 340% | 277.3% | -59% | 120.6% | -2.7% | 97.3% | 36.1% | -28.6% | - |
| BVPS (₹) ⓘ | 23.8 | 23.8 | 24.1 | 24.4 | 24.1 | 24.7 | 25.3 | 26.3 | 27.7 | 28.6 | 28.9 |
| Adj Net Profit ⓘ | -2 | 0.1 | 0.5 | 1.7 | 0.7 | 1.6 | 1.5 | 3 | 4.1 | 2.9 | 1 |
| Cash Flow from Ops. ⓘ | 2.4 | 3.4 | 3 | 5.8 | 4.2 | 5 | 2.7 | 4.4 | 4.4 | 5.7 | - |
| Debt/CF from Ops. ⓘ | 0.4 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.5% | 4.6% | 14.2% | 2.5% | ||||
| Adj EPS ⓘ | NA | 32.7% | 24.2% | -28.6% | ||||
| BVPSⓘ | 2.1% | 3.5% | 4.1% | 3.2% | ||||
| Share Price | 19.2% | 24% | 11.7% | -32.2% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -4 | 0.2 | 0.9 | 3.4 | 1.4 | 3.1 | 2.9 | 5.6 | 7.3 | 5 | 2.4 |
| Op. Profit Mgn % ⓘ | 4.6 | 10.2 | 9.8 | 11.5 | 8.4 | 9.8 | 11.2 | 15.3 | 16.4 | 13.8 | 10.6 |
| Net Profit Mgn % ⓘ | -6.7 | 0.3 | 1.4 | 4.5 | 1.8 | 3.8 | 4.7 | 7.7 | 8.7 | 6 | 2.9 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 115 | 98 | 93 | 96 | 92 | 72 | 88 | 76 | 71 | 79 | 50 |
| Cash Conv. Cycle ⓘ | 4 | -1 | -1 | -9 | -7 | -6 | -9 | -12 | -7 | 1 | 23 |
Sales growth is growing at healthy rate in last 3 years 14.20%
Net Profit is growing at healthy rate in last 3 years 24.24%
Return on Equity has declined versus last 3 years average to 2.40%
Sales growth is not so good in last 4 quarters at 0.11%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.7 | - |
| TTM Sales (₹ Cr.) | 48.7 | - |
| BVPS (₹.) ⓘ | 28.9 | - |
| Reserves (₹ Cr.) ⓘ | 39 | - |
| P/BV ⓘ | 2.26 | - |
| PE ⓘ | 96.52 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 44.10 / 102.00 |
| All Time Low / High (₹) | 4.43 / 110.90 |
| Market Cap (₹ Cr.) | 136 |
| Equity (₹ Cr.) | 20.8 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 40.5 |
| Pledged * | 4.16 | 4.15 | 4.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30 | 31 | 34 | 38 | 38 | 41 | 32 | 39 | 47 | 48 |
| Operating Expenses ⓘ | 29 | 28 | 31 | 34 | 35 | 37 | 29 | 33 | 39 | 42 |
| Manufacturing Costs | 8 | 7 | 7 | 9 | 9 | 10 | 8 | 9 | 10 | 11 |
| Material Costs | 9 | 9 | 11 | 11 | 11 | 12 | 10 | 12 | 15 | 15 |
| Employee Cost | 5 | 6 | 7 | 8 | 8 | 8 | 7 | 7 | 9 | 9 |
| Other Costs ⓘ | 7 | 6 | 5 | 6 | 6 | 7 | 4 | 5 | 6 | 6 |
| Operating Profit ⓘ | 1 | 3 | 3 | 4 | 3 | 4 | 4 | 6 | 8 | 7 |
| Operating Profit Margin (%) | 4.6% | 10.2% | 9.8% | 11.4% | 8.4% | 9.8% | 11.2% | 15.2% | 16.4% | 13.8% |
| Other Income ⓘ | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 4 | 4 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 4 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -2 | 0 | 0 | 2 | 1 | 1 | 2 | 4 | 6 | 4 |
| Tax ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Profit After Tax | -2 | 0 | 0 | 2 | 1 | 1 | 2 | 3 | 4 | 3 |
| PAT Margin (%) | -6.6% | 0.3% | 1.3% | 4.6% | 1.8% | 2.6% | 4.8% | 7.7% | 8.7% | 6.0% |
| Adjusted EPS (₹) | -1.0 | 0.1 | 0.2 | 0.8 | 0.3 | 0.5 | 0.8 | 1.4 | 2.0 | 1.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 234% | 60% | 0% | 0% | 66% | 35% | 26% | 36% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 49 | 49 | 50 | 51 | 50 | 51 | 53 | 55 | 58 | 59 |
| Share Capital ⓘ | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves ⓘ | 29 | 29 | 29 | 30 | 29 | 30 | 32 | 34 | 37 | 39 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Payables | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 3 | 3 |
| Others Liabilities ⓘ | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 |
| Total Liabilities ⓘ | 56 | 55 | 55 | 57 | 56 | 57 | 58 | 61 | 63 | 66 |
Fixed Assets | ||||||||||
| Gross Block | 74 | 75 | 75 | 80 | 81 | 82 | 82 | 87 | 90 | 98 |
| Accumulated Depreciation | 27 | 31 | 34 | 37 | 36 | 39 | 41 | 43 | 46 | 49 |
| Net Fixed Assetsⓘ | 47 | 44 | 41 | 43 | 44 | 43 | 41 | 44 | 44 | 49 |
| CWIP ⓘ | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
| Trade Receivables | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Cash Equivalents | 1 | 2 | 3 | 4 | 3 | 7 | 10 | 9 | 8 | 7 |
| Others Assetsⓘ | 5 | 5 | 7 | 7 | 6 | 5 | 5 | 5 | 6 | 6 |
| Total Assets ⓘ | 56 | 55 | 55 | 57 | 56 | 57 | 58 | 61 | 63 | 66 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 2 | 3 | 3 | 6 | 4 | 5 | 3 | 4 | 4 | 6 |
| PBT ⓘ | -2 | 0 | 0 | 2 | 1 | 2 | 2 | 4 | 6 | 4 |
| Adjustment ⓘ | 5 | 4 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 |
| Changes in Working Capital ⓘ | -0 | -1 | -0 | 1 | 1 | 1 | -1 | -1 | -2 | -0 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -1 |
| Cash Flow From Investing Activity ⓘ | -5 | -1 | -1 | -4 | -4 | -1 | 0 | -4 | -2 | -5 |
| Capex | -5 | -1 | -1 | -4 | -5 | -1 | 0 | -5 | -3 | -5 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Cash Flow From Financing Activityⓘ | 2 | -1 | 0 | -2 | -1 | 0 | 0 | -2 | -2 | -3 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | -1 | 0 | 0 | 0 | -1 | -1 | -1 |
| Others ⓘ | 1 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | -1 | -2 |
| Net Cash Flow ⓘ | 0 | 2 | 2 | 0 | -1 | 4 | 3 | -1 | 0 | -2 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -3.93 | 0.2 | 0.89 | 3.47 | 1.41 | 2.1 | 3.02 | 5.56 | 7.27 | 4.98 |
| ROCE (%) | -4.14 | 0.27 | 1.13 | 3.71 | 1.66 | 3.32 | 4.07 | 8 | 10.43 | 7.19 |
| Asset Turnover Ratio | 0.52 | 0.56 | 0.62 | 0.68 | 0.68 | 0.72 | 0.56 | 0.65 | 0.76 | 0.75 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | 3 | 4 | 5 | 1.5 | 1.33 | 1 | 2 | Working Capital Days |
| Receivable Days | 5 | 5 | 6 | 9 | 9 | 6 | 8 | 6 | 7 | 9 |
| Inventory Days | 41 | 34 | 25 | 20 | 22 | 19 | 22 | 19 | 20 | 23 |
| Payable Days | 119 | 118 | 87 | 108 | 111 | 88 | 107 | 96 | 82 | 79 |
Lotus Eye Care Hospital was originally incorporated as ‘Kalaivani Health Centre Pvt. Ltd.’on March 14,1997 under the Companies Act, 1956 vide Certificate of Incorporation issued by the Registrar of Companies, Tamil Nadu, Coimbatore. The name of the Company was changed to ‘Lotus Eye Care Hospital Pvt. Ltd. on January 23, 2006 and subsequently to ‘Lotus Eye Care Hospital Limited’ upon conversion into Public Limited Company on October 16, 2007 and a fresh certificate of incorporation has been obtained from Registrar of Companies, Tamil Nadu, Coimbatore.
Lotus Eye Care Hospital is a hi-tech super specialty eye care hospital catering its value added service to the society since inception
Lotus is known for its excellence in Ophthalmic services with personalized care. Lotus is committedly pioneering in the technological revolution in eye care and rendering service to thousands of patients from across the globe to see the world better than ever before.
In the year 1998 Lotus introduced Multi Scan Lasik and in the year 2002 Wave front based Esiris Custom Lasik for the first time in India. Lotus was the first Eye Hospital in South East Asia to have performed Epilasik in July 2004. In the year June 2005 Lotus introduced the most advanced technology of Zyoptix Z100 and combined two superior technologies Epilasik and Zyoptix known as Zyoptix Integrated Epilasik to achieve Supervision.
Lotus has a vision of “empowering eyes to illuminate livesâ€. Lotus Eye Care group is marching towards its vision of becoming India’s best Corporate Hospital with branches in strategic locations where quality eye care is in need, and render world class eye care service to the society.
Dr.SK.Sundaramoorthy and his team of ophthalmic experts, who have highly qualified with vast experience in each specialty, render comprehensive eye care to hundreds of patients daily at their state of the art eye hospitals in Coimbatore, Tirupur and Salem in South India.
Services offered by the company:
Milestones:
Achievements/ recognition:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
